Archives of Medical Research
Volume 40, Issue 4 , Pages 264-267 , May 2009

N-Acetyltransferase 2 (NAT2) Polymorphism in Patients with Atopic Asthma

  • Andrzej Pawlik

      Affiliations

    • Department of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian Medical University, Szczecin, Poland
    • Corresponding Author InformationAddress reprint requests to: Andrzej Pawlik, Department of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian Medical University, 70-111 Szczecin, Poland
    • ,
  • Zygmunt Juzyszyn

      Affiliations

    • Department of Medical Chemistry, Pomeranian Medical University, Szczecin, Poland
    • ,
  • Barbara Gawronska-Szklarz

      Affiliations

    • Department of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian Medical University, Szczecin, Poland

Received 13 November 2008 ,Accepted 3 March 2009.

References 

  1. Bener A, Ehlayel M, Sabbah A. The pattern and genetics of pediatric extrinsic asthma risk factors in polluted environment. Allerg Immunol. 2007;39:58–63
  2. Gern JE. Viral respiratory infection and the link to asthma. Pediatr Infect Dis J. 2008;27(10 suppl):S97–S103
  3. Kabesch M, Depner M, Dahmen I, et al. Polymorphisms in eosinophil pathway genes, asthma and atopy. Allergy. 2007;62:423–428
  4. Saglani S, Bush A. The early-life origins of asthma. Curr Opin Allergy Clin Immunol. 2007;7:83–90
  5. Daly AK, Cholerton S, Armstrong M, Idle JR. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility. Environ Health Perspect. 1994;102(suppl 9):55–61
  6. Safuanova G Sh. Polymorphism of xenobiotic detoxication genes in patients with iron deficiency anemia. Klin Lab Diagn. 2003;7:40–42
  7. Fogel WA, Lewinski A, Jochem J. Histamine in food: is there anything to worry about?. Biochem Soc Trans. 2007;35:349–352
  8. Seiler N. Catabolism of polyamines. Amino Acids. 2004;26:217–233
  9. Mitchell KR, Warshawsky D. Xenobiotic inducible regions of the human arylamine N-acetyltransferase 1 and 2 genes. Toxicol Lett. 2003;139:11–23
  10. Delomenie C, Sica L, Grant DM, Krishnamoorthy R, Dupret JM. Genotyping of the polymorphic N-acetyltransferase (NAT2∗) gene locus in two native African populations. Pharmacogenetics. 1996;6:177–185
  11. Hein DW, Ferguson RJ, Doll MA, Rustan TD, Gray K. Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes. Hum Mol Genet. 1994;3:729–734
  12. Sabbagh A, Langaney A, Darlu P, Gérard N, Krishnamoorthy R, Poloni ES. Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet. 2008;9:21
  13. Spielberg SP. N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Pharmacokinet Biopharm. 1996;24:509–519
  14. Rychlik-Sych M, Skretkowicz J, Gawronska-Szklarz B, Górnik W, Sysa-Jedrzejowska A, Skretkowicz-Szarmach K. Acetylation genotype and phenotype in patients with systemic lupus erythematosus. Pharmacol Rep. 2006;58:22–29
  15. Kumagi S, Komada F, Kita T, et al. N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis. Pharm Res. 2004;21:324–329
  16. Tamer L, Ercan B, Ates NA, et al. N-acetyltransferase 2 gene polymorphism in patients with colorectal carcinoma. Cell Biochem Funct. 2006;24:131–135
  17. Crabtree MD, Fletcher C, Churchman M, Hodgson SV, Neale K, Phillips RK, et al. Analysis of candidate modifier loci for the severity of colonic familial adenomatous polyposis, with evidence for the importance of the N-acetyl transferases GUT. 2004;53:271–276
  18. Patkowski J, Malolepszy J, Milejski P, Orzechowska-Juzwenko K, Nittner-Marszalska M. Acetylation phenotype in atopic diseases. Pol Tyg Lek. 1987;42:870–873
  19. Zielinska E, Niewiarowski W, Bodalski J, Stanczyk A, Bolanowski W, Rebowski G. Arylamine N-acetyltransferase (NAT2) gene mutations in children with allergic diseases. Clin Pharmacol Ther. 1997;62:635–642
  20. Global strategy for asthma management and prevention. NHLBI/WHO Workshop Report, NIH Publication No. 02-3659, February 2002.
  21. Gawronska-Szklarz B, Luszawska-Kutrzeba T, Czaja-Bulsa G, Kurzawski G. Relationship between acetylation polymorphism and risk of atopic diseases. Clin Pharmacol Ther. 1999;65:562–569
  22. Gustincich S, Manfioletti G, Del Sal G, Schneider C, Carninci P. A fast method for high-quality genomic DNA extraction from whole human blood. Biotechniques. 1991;11:298–302
  23. Spurr NK, Gough AC, Chinegwundoh FI, Smith CA. Polymorphisms in drug-metabolizing enzymes as modifiers of cancer risk. Clin Chem. 1995;41:1864–1869
  24. Mrozikiewicz PM, Cascorbi I, Brockmöller J, Roots I. Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population. Clin Pharmacol Ther. 1996;59:376–382
  25. Gawronska-Szklarz B, Pawlik A, Czaja-Bulsa G, Górnik W, Luszawska-Kutrzeba T, Wrzesniewska J. Genotype of N-acetyltransferase 2 (NAT2) polymorphism in children with immunoglobulin E-mediated food allergy. Clin Pharmacol Ther. 2001;69:372–378
  26. Wikman H, Piirila P, Rosenberg C, et al. N-Acetyltransferase genotypes as modifiers of diisocyanate exposure-associated asthma risk. Pharmacogenetics. 2002;12:227–233
  27. Nacak M, Aynacioglu AS, Filiz A, et al. Association between the N-acetylation genetic polymorphism and bronchial asthma. Br J Clin Pharmacol. 2002;54:671–674
  28. Batra J, Sharma SK, Ghosh B. Arylamine N-acetyltransferase gene polymorphisms: markers for atopic asthma, serum IgE and blood eosinophil counts. Pharmacogenomics. 2006;7:673–682
  29. Tamer L, Calikoglu M, Aras Ates N, Yildirim H, Karakas S, Atik U. Relationship between N-acetyl transferase-2 gene polymorphism and risk of bronchial asthma. Tuberk Toraks. 2006;54:137–143
  30. Makarova SI, Vavilin VA, Lyakhovich VV, Gavalov SM. Allele NAT2∗5 determines resistance to bronchial asthma in children. Bull Exp Biol Med. 2000;129:575–577
  31. Kopferschmitt-Kubler MC, Frossard N, Rohde G, Pauli G. Increase in non-specific bronchial hyperresponsiveness without specific response to isocyanate in isocyanate-induced asthma: a pilot study. Respir Med. 1998;92:1093–1098
  32. Meredith SK, Bugler J, Clark RL. Isocyanate exposure and occupational asthma: a case-referent study. Occup Environ Med. 2000;57:830–836
  33. Klein DC. Arylalkylamine N-acetyltransferase: “the Timenzyme”. J Biol Chem. 2007;282:4233–4237
  34. Ménard G, Turmel V, Bissonnette EY. Serotonin modulates the cytokine network in the lung: involvement of prostaglandin E2. Clin Exp Immunol. 2007;150:340–348
  35. Bayer H, Mueller T, Myrtek D, et al. Serotoninergic receptors on human airway epithelial cells. Am J Respir Cell Mol Biol. 2007;36:85–93
  36. Garcia-Maurino S, Gonzalez-Haba MG, Calvo JR, et al. Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4+ cells: a possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. J Immunol. 1997;159:574–581
  37. Sutherland ER, Ellison MC, Kraft M, Martin RJ. Elevated serum melatonin is associated with the nocturnal worsening of asthma. J Allergy Clin Immunol. 2003;112:513–517
  38. Rahamimoff R, Bruderman I. Changes in pulmonary mechanics induced by melatonin. Life Sci. 1965;4:1383–1389

PII: S0188-4409(09)00043-5

doi: 10.1016/j.arcmed.2009.03.003

Archives of Medical Research
Volume 40, Issue 4 , Pages 264-267 , May 2009

Article Tools